Design and In Vitro Evaluation of Atovaquone Nanosuspension Prepared by pH Based and Anti-solvent Based Precipitation Method
Source abstract
Abstract
Abstract The aim of the research was to design a novel pH based precipitation method for formulation of atovaquone nanosuspension. The study compares efficiency of two bottom-up methods namely, pH and anti-solvent based precipitation to reduce particle size of atovaquone. The anti-solvent precipitation method uses tetrahydrofuran as the solvent with poloxamer and povidone as stabilizers. The pH based precipitation method includes sodium hydroxide as basifying agent in combination with poloxamer as wetting agent, povidone and phospholipids as stabilizing agents and citric acid as the acidifying agent for precipitation. The optimized nanosuspension obtained in the bottom-up step was subjected to microfluidization in the top-down step. It was found that phospholipids helped in improving physical stability of nanosuspension. The water solubility of atovaquone was improved from 0.74 to 11.98 μg/ml in the adsorbed pH based nanosuspension. The particle size of nanosuspension formed using anti-solvent based precipitation was 340 ± 20 nm and the adsorbed nanosuspension had dissolution of 23% in 2 h. Conversely, the particle size of nanosuspension formed using pH based precipitation was 297 ± 10 nm and the adsorbed nanosuspension showed dissolution of around 40% in 2 h. Atovaquone nanosuspension prepared by pH based precipitation method was stable till 6 months.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Innovative Microfluidic and Catalytic Techniques Innovation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (23)
Show source-provided references
1. Antimalarial pharmacology and therapeutics of atovaquone
2. MINIREVIEW antiparasitic agent atovaquone10.1128/AAC.46.5.1163-1173.2002 ↗
3. In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs10.1016/S0928-0987(00)00181-0 ↗
4. Bioavailability enhancement of atovaquone using hot melt extrusion technology
5. Solid lipid nanoparticles of atovaquone based on 24 full-factorial design
6. Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria research article10.2217/nnm.13.61 ↗
7. Dissolution enhancement of atovaquone through cyclodextrin complexation and phospholipid solid dispersion
8. Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics10.1016/S0378-5173(02)00556-2 ↗
9. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis10.1016/S0020-7519(00)00053-9 ↗
10. Technology in the delivery of poorly soluble drugs: an overview10.2174/156720111795767988 ↗
11. Kumar · 2016
12. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis10.1128/AAC.45.6.1771-1779.2001 ↗
13. Disouza, case studies on pharmaceutical product development
14. Dearn · 2003
15. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study10.3109/10717544.2014.923066 ↗
16. Stable drug encapsulation in micelles and microemulsions10.1016/j.ijpharm.2007.08.057 ↗
17. Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken design
18. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation10.1016/j.ijpharm.2013.06.039 ↗
19. Preparation and characterization of ketoprofen nanosuspension for solubility and dissolution velocity enhancement
20. Amighi · 2010
21. Core/shell nanocomposites produced by superfast sequential microfluidic nanoprecipitation10.1021/acs.nanolett.6b03251 ↗
22. Production of pure drug nanocrystals and Nano Co-crystals by confinement methods10.1016/j.addr.2018.05.002 ↗
23. Stabilizing agents for drug nanocrystals: effect on biovailability10.3390/pharmaceutics8020016 ↗